Phase_I_study_of_weekly_intravenous_infusions_of_CPT-11,_a_new_derivative_of_camptothecin,_in_the_treatment_of_advanced_non-small-cell_lung_cancer._7-Ethyl-10-4-(1-piperidino)-1-piperidinocarbonyloxy-camptothecin_(CPT-11)_is_a_novel_camptothecin_derivative_that_has_been_selected_for_clinical_evaluation_because_of_its_broad_spectrum_of_antitumor_activity_in_animal_models_and_its_unique_inhibitory_effects_on_mammalian_DNA_topoisomerase_I._Seventeen_patients_with_advanced_non-small-cell_lung_cancer_were_treated_with_CPT-11_at_weekly_dose_levels_ranging_from_50_to_150_mg/m2._At_least_three_weekly_doses_were_given_to_all_patients_except_four,_and_a_total_of_74_weekly_doses_were_given_to_the_17_patients._The_dose-limiting_toxic_effects_were_myelosuppression_(predominantly_leukopenia)_and_unpredictable_diarrhea._Gastrointestinal_toxic_effects_were_severe_and_not_well_controlled_by_standard_therapy_in_some_patients._Interpatient_variability_of_toxic_effects_was_substantial_(including_two_deaths)_and_did_not_correlate_with_the_pharmacokinetic_parameters_of_CPT-11_and_7-ethyl-10-hydroxycamptothecin,_its_major_metabolite._Two_previously_untreated_patients,_who_received_doses_of_100_and_125_mg/m2,_had_partial_responses_lasting_3.2_and_4.0_months,_respectively._The_maximum_tolerated_dose_on_this_schedule_was_100_mg/m2,_which_we_also_recommend_as_a_starting_dose_for_phase_II_studies._This_schedule_appears_to_allow_a_CPT-11_dose_intensity_which_is_double_the_dose_intensity_possible_on_a_once-a-month_schedule._However,_careful_supervision_to_assess_gastrointestinal_toxic_effects_and_myelosuppression_is_indispensable_because_of_wide_individual_differences_in_drug_tolerance.